- Reaction score
- 122
Intellasia East Asia News - Hope Medicine Inc. Announced Dr. Henri Nico Doods as Chief Executive Officer
SHANGHAI, Aug. 30, 2021 /PRNewswire/ -- Hope Medicine Inc. ('HopeMed'), a clinical stage innovative biopharmaceutical company, has recently announced that the former President and Head of Researc...
www.intellasia.net
here you go @RolfLeeBuckler
"and most importantly a frontrunner asset HMI-115 that has got IND approval from the US FDA for Phase II clinical trial in endometriosis, and patient recruitment for the US Phase II clinical trial will start by Q4 of this year."
they have FDA approval for a clinical trial for the indication of "endometriosis". they do not have even FDA approval to conduct a trial in any other condition at this point in time.
just as i said, you do not develop such an expensive anti body for a condition that is not covered by insurance and while being underserved does really not have that much of a market potential. they will start clinical trial for the vagine condition soon. when will they start for AA? my guess is it will be the same as with Cassiopea where one product will be 5-6 years behind. now keep in mind that not every management is as aggressively incompetent as that shitty company from Italy but still, i would highly doubt that there will be a clinical phase 2 trial of this compound for the indication of AA before 2025. sad that hair loss is one again getting the short end of the stick but this is to be expected.
edit: the trial wont even start in Q4, recruitment will so add another 6 months on top of that time line. also multi center does not mean trial for multiple conditions, it just means in multiple institutes. really a bummer and i wish the drug would not work for the vagine disease
Last edited: